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background:  Aortic stenosis is the most common valvular heart disease, affecting 4.6% of adults older than 75 years. Patients at high 
risk of surgical complication were historically treated medically. Transcatheter Aortic Valve Implantation (TAVI) allowed access to a therapy 
that reduced symptoms and mortality for these patients. Whilst mortality benefits are well proven little real world long term data analysis of 
these groups is available in terms of survival, admission profiles and costs.
methods:  Electronic patient letters were search for patients with a diagnosis of severe aortic stenosis and a formal outpatient Surgical 
Turn Down (STD). The second group was the first 80 cases of TAVI in South Wales. 2 years prior to and 5 years following TAVI or STD 
were assessed. Patient data was pseudo-anonymised and using the SAIL databank data was extracted from Office National Statistics, 
Patient Episode Database for Wales (PEDW) and GP databases for the two groups.
results:  80 TAVI (59.7%) and 54 (40.3%) STD patients were assessed. TAVI patients were older (81.78 vs 79.18; p<0.05), more likely to 
be male (59.1% vs 49.3%; p<0.05), baseline co-morbidities were balanced. During follow up mortality in TAVI vs STD was 19.2% vs 41.7%; 
p<0.05. More admissions per year in the TAVI group prior to TAVI / STD (Mean 1.92 vs 1.32 p=0.039). Post TAVI / STD admissions and 
spell lengths were decreased in the TAVI group (Mean 0.86 vs 1.84 p=0.0001 and 10.05 vs 18.28 p=0.18). Post TAVI / STD (excluding TAVI 
implant admission) costs of admission per year were less in the TAVI group (£6059 vs £11001 p=0.15). The TAVI implant admission spell 
length had a significant impact on the overall cost of this therapy. Individual co-morbidities and age did not predict TAVI implant spell length. 
Patients investigated as inpatients rather than outpatients significantly increased TAVI implant spell length as well as increased mortality.
Conclusion:  TAVI patients were more likely to survive and avoid hospital admissions. Significant reductions in admission costs post TAVI 
were adversely affected by long admissions during the TAVI implant. Inpatient rather than outpatient investigation leading to TAVI had a 
major influence on cost and mortality.
